Print

Purpose

This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Confirmed clinical diagnosis of Cystic Fibrosis (CF) who are homozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation - Stable pulmonary status - Lung function >= 40 and <= 90% of predicted normal for age, gender and height at Screening

Exclusion Criteria

  • History of solid organ or hematopoietic transplant - Cirrhosis with portal hypertension - Use of CFTR modulator therapy within 60 days prior to Screening

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Part 1: ABBV-3067 + Placebo 		Participants will receive various dosing regimens for ABBV-3067 plus placebo ABBV-2222 taken orally depending on arm assignment.
  • Drug: ABBV-3067
    Tablet or capsule taken orally
  • Drug: Placebo ABBV-2222
    Capsule taken orally
Experimental
Part 1: ABBV-3067 + ABBV-2222 		Participants will receive fixed dose of ABBV-3067 plus various dosing regimens for ABBV-2222 taken orally depending on arm assignment.
  • Drug: ABBV-3067
    Tablet or capsule taken orally
  • Drug: ABBV-2222
    Capsule taken orally
Placebo Comparator
Part 1 and Part 2: Placebo 		Participants in Part 1 and Part 2 will receive placebo ABBV-3067 plus placebo ABBV-2222 taken orally.
  • Drug: Placebo ABBV-3067
    Tablet or capsule taken orally
  • Drug: Placebo ABBV-2222
    Capsule taken orally
Experimental
Part 2: ABBV-3067 + ABBV-2222 		Participants will receive various dosing regimens for ABBV-3067 plus a fixed dose of ABBV-2222 taken orally depending on arm assignment.
  • Drug: ABBV-3067
    Tablet or capsule taken orally
  • Drug: ABBV-2222
    Capsule taken orally

Recruiting Locations

University of Arkansas /ID# 212541
Little Rock, Arkansas 72205

Tampa General Hospital /ID# 212342
Tampa, Florida 33606

University of Iowa Hospitals and Clinics /ID# 212351
Iowa City, Iowa 52242

Washington University-School of Medicine /ID# 212352
Saint Louis, Missouri 63110

Nationwide Childrens Hospital /ID# 213158
Columbus, Ohio 43205-2664

Medical University of South Carolina /ID# 212187
Charleston, South Carolina 29425

Vanderbilt University Medical Center /ID# 212353
Nashville, Tennessee 37232

University of Utah /ID# 212350
Salt Lake City, Utah 84112-5500

More Details

NCT ID
NCT03969888
Status
Recruiting
Sponsor
AbbVie

Study Contact

ABBVIE CALL CENTER
844-663-3742
abbvieclinicaltrials@abbvie.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.